Increased use of Paxlovid, the antiviral drug used to treat COVID-19, could prevent hundreds of thousands of hospitalizations and save tens of billions of dollars a year, according to a new epidemiological model published by researchers at The University of Texas at Austin.
Arcus deprioritizes Gilead-partnered drug in prostate cancer, the latest hiccup in $1.6B collaboration
Arcus Biosciences is reducing further investment on its adenosine receptor antagonist in prostate cancer after reviewing interim data, according to its second quarter report. In
August 8, 2023